Jeremy Clarkson has spoken publicly about trying Ozempic, experiencing difficult side effects, and later switching to Mounjaro. His journey has sparked genuine conversation about weight loss injections in the UK. Here is what his experience actually tells us, and what it does not.
Jeremy Clarkson is not the first famous face to discuss weight loss injections publicly. But as one of Britain’s most recognisable broadcasters, his candid account of trying Ozempic and later switching to Mounjaro has landed differently. He speaks plainly, in language millions of people trust. And for many women quietly researching treatment options, his story has felt unexpectedly relatable.
What Happened?
Clarkson first discussed Ozempic in his widely-read Sunday Times column, describing it as genuinely unpleasant to use. According to his published columns, he experienced significant nausea and described the side effects as worse than he had anticipated. He was not subtle about it.
He subsequently wrote about switching to Mounjaro, the brand name for tirzepatide, which targets both GLP-1 and GIP receptors. His tone shifted noticeably. He reported better tolerability and visible results. The columns attracted enormous reader response and were widely picked up by UK national press throughout 2025 and into 2026.
Clarkson has also spoken about his broader health concerns, including a serious heart procedure he underwent in 2023. Writing in The Sunday Times, he connected his weight and his cardiac health directly. That framing matters. This was not vanity. It was a man in his sixties describing a medical motivation most readers could understand.
It is worth noting what Clarkson has not done. He has not endorsed a specific clinic. He has not claimed dramatic transformation in unrealistic timescales. He has not described the treatment as easy. That relative honesty is precisely why his account has cut through where glossier celebrity endorsements have not.
Why Does This Matter?
For the UK obesity medicine conversation, Clarkson’s columns have done something that clinical papers and public health campaigns have struggled to do. They have made the messy reality of these treatments visible to a mainstream audience.
The nausea he described with Ozempic is real and well-documented. According to the MHRA’s published product information for semaglutide, gastrointestinal side effects including nausea, vomiting and diarrhoea are among the most commonly reported. Many patients do switch medicines or adjust doses to manage them. Clarkson’s experience was not unusual. It was just unusually public.
His switch to Mounjaro also reflects a genuine clinical pattern. Researchers reporting in The Lancet have noted that tirzepatide produced greater average weight loss than semaglutide in head-to-head trial data. Some patients who find semaglutide difficult do report better tolerance on tirzepatide, though responses vary considerably between individuals.
The wider significance is about normalisation. If you are a 50-year-old woman weighing up private treatment and feeling quietly embarrassed about it, watching a 66-year-old man write openly about his injections in a national newspaper shifts something. It removes a layer of stigma that clinical guidance alone cannot touch.
For anyone at the stage of comparing options and costs, our Mounjaro Price Comparison UK guide is a useful starting point before committing to a provider.
There is also a less comfortable dimension to this story. Clarkson has a platform and a Sunday Times column. He accessed private prescribing without difficulty. According to NHS England, Mounjaro is currently available on the NHS only through specialist weight management services, and waiting lists remain long in most areas. The experience Clarkson describes is largely a private healthcare experience. That gap is real and worth naming.
What Happens Next?
Clarkson’s ongoing columns suggest he is continuing treatment and monitoring results. Whether he maintains the weight loss long-term will matter more than any short-term result he has reported so far.
For the broader UK market, his profile has almost certainly accelerated interest in Mounjaro specifically. Search data from Google Trends UK showed consistent spikes in Mounjaro-related searches following major press coverage of his columns in late 2025. That kind of celebrity-driven demand creates its own pressures on supply chains and clinic capacity.
The MHRA continues to monitor all approved weight loss medicines in the UK. Anyone choosing a private provider should ensure they are using a registered, CQC-regulated service. Our Regulation and Policy section covers what legitimate prescribing should look like and what to avoid.
Looking further ahead, next-generation treatments such as retatrutide may eventually offer further options for patients who do not respond well to current medicines. Our Retatrutide UK Guide covers where that research currently stands.
What This Means For UK Patients
Clarkson’s story is useful, but it has limits. His experience validates something important: switching medicines when side effects are severe is a legitimate option, not a failure. His more positive experience on Mounjaro reflects what many patients report. But his journey was shaped by private access, personal wealth and a platform that most patients do not have.
The honest lesson here is to go in with realistic expectations. Side effects are common, especially early on. Switching is possible. Results take time. And finding a reputable, regulated provider matters far more than which celebrity happens to be using the same medicine. If cost is a consideration, it is worth taking time to compare Mounjaro prices across regulated UK providers before making a decision.
Frequently Asked Questions
Did Jeremy Clarkson switch from Ozempic to Mounjaro?
Yes. According to his published columns in The Sunday Times, Clarkson described significant nausea on Ozempic and later switched to Mounjaro. He reported better tolerability on tirzepatide, though he was clear that neither treatment was without challenges.
Is it normal to switch from Ozempic to Mounjaro due to side effects?
It happens more often than many patients realise. According to MHRA prescribing guidance, gastrointestinal side effects are among the most common reasons patients and clinicians review their treatment choice. Some people do tolerate tirzepatide differently to semaglutide, though this varies between individuals.
Can I get Mounjaro on the NHS instead of going private?
Currently, NHS access to Mounjaro is limited to specialist weight management services, according to NHS England. Waiting times are significant in most areas. Many patients are choosing regulated private clinics in the meantime. If you are comparing private costs, our Mounjaro Price Comparison UK page is a useful resource.
Should celebrity experiences influence my treatment decisions?
Treat them as a prompt to research, not a prescription. According to the British Medical Association, individual responses to weight loss medicines vary considerably based on health history, existing conditions and dosing. A celebrity’s published experience is anecdote, not clinical guidance. Always consult a registered prescriber.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
Get the UK peptide medicine briefing in your inbox.
Free weekly. No spam. Unsubscribe any time.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment. Information correct at time of publication. The Peptide Brief updates articles when guidance changes.
